Akassa Marius Bernard Djako

QSAR, Pharmacophore and Molecular Docking Studies for the Design of Novel Arylamide-derived Inhibitors of Mycobacterium tuberculosis

Adama Niaré, Abadê Ange-Boris N’guessan, Akassa Marius Bernard Djako, Georges Stephane Dembele, Mamadou Guy-Richard Koné & Yaya Yéo · Chemical Science International Journal · 2024

Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It remains a significant public health challenge worldwide. In 2022, approximately 10.6 million people were diagnosed with tuberculosis, and 1.3 million individuals lost their lives to the d...

Open access Research Article 10.9734/CSJI/2024/v33i6939

Structure-Based Design and In silico Evaluation of Novel Donepezil Analogues as Potent Inhibitors of Human Acetylcholinesterase for Alzheimer's Disease Therapy

Issouf Fofana, Aboubakar Traoré, Bafétigué Ouattara, Akassa Marius Bernard Djako, N'goran Urbain Florent Niangoran, Souleymane Konate & Eugene Megnassan · Journal of Pharmaceutical Research International · 2025

Alzheimer's disease (AD) accounts for 60 to 70% of dementias worldwide. This condition is primarily associated with the decrease in acetylcholine (ACh) levels, due to the action of human acetylcholinesterase (AChE). The lack of a curative treatment for Alzheimer's disease undersc...

Open access Research Article 10.9734/jpri/2025/v37i127776